Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2009-04

AUTHORS

Giuseppe Gullo, Daniela Bettio, Valter Torri, Giovanna Masci, Piermario Salvini, Armando Santoro

ABSTRACT

To explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC. More... »

PAGES

179

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y

DOI

http://dx.doi.org/10.1007/s10637-008-9155-y

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1016696899

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18663410


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antibodies, Monoclonal, Humanized", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Gene Amplification", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, erbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "In Situ Hybridization, Fluorescence", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Predictive Value of Tests", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Trastuzumab", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Humanitas Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, (Milan), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gullo", 
        "givenName": "Giuseppe", 
        "id": "sg:person.01223342332.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223342332.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Humanitas Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Laboratory of Cytogenetics, Istituto Clinico Humanitas IRCCS, Rozzano, (Milan), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bettio", 
        "givenName": "Daniela", 
        "id": "sg:person.0726433703.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726433703.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Mario Negri Institute for Pharmacological Research", 
          "id": "https://www.grid.ac/institutes/grid.4527.4", 
          "name": [
            "Clinical Oncology Research Unit, Istituto di Ricerche Farmacologiche \u201cMario Negri\u201d, Milan, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Torri", 
        "givenName": "Valter", 
        "id": "sg:person.01213013520.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213013520.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Humanitas Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, (Milan), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masci", 
        "givenName": "Giovanna", 
        "id": "sg:person.01203725612.04", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203725612.04"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Medical Oncology Unit, Cliniche Gavazzeni, Bergamo, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Salvini", 
        "givenName": "Piermario", 
        "id": "sg:person.01357677760.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357677760.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Humanitas Research Hospital", 
          "id": "https://www.grid.ac/institutes/grid.417728.f", 
          "name": [
            "Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, (Milan), Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Santoro", 
        "givenName": "Armando", 
        "id": "sg:person.01277354144.26", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277354144.26"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.3816/cbc.2005.n.026", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001198940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.04.173", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003035955"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3816/cbc.2001.n.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003466394"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.copbio.2007.11.004", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007493316"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012929330", 
          "https://doi.org/10.1038/sj.bjc.6602926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.bjc.6602926", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012929330", 
          "https://doi.org/10.1038/sj.bjc.6602926"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.8957", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019255637"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2006.11.019", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022644824"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2006.09.2775", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026719751"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdj905", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031702252"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200103153441101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031768583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ccr.2007.08.030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034133737"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006111117877", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037590396", 
          "https://doi.org/10.1023/a:1006111117877"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1097/01.mp.0000052102.90815.82", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043809974", 
          "https://doi.org/10.1097/01.mp.0000052102.90815.82"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdl475", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046368550"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djk134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047572985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djk134", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047572985"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1023/a:1006262324959", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047763314", 
          "https://doi.org/10.1023/a:1006262324959"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049278910"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-06-1304", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049548242"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.3798106", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1062621480"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.20.3.719", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064202789"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.20.3.719", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083941918"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2009-04", 
    "datePublishedReg": "2009-04-01", 
    "description": "To explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10637-008-9155-y", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "27"
      }
    ], 
    "name": "Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer", 
    "pagination": "179", 
    "productId": [
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-008-9155-y"
        ]
      }, 
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "4f8dd6d38b5348ae802a862450e05f0418acb3e4f2fc9d4658c21e7bd7bcaad5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1016696899"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18663410"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-008-9155-y", 
      "https://app.dimensions.ai/details/publication/pub.1016696899"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-15T09:13", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000376_0000000376/records_56164_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs10637-008-9155-y"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-008-9155-y'


 

This table displays all metadata directly associated to this object as RDF triples.

241 TRIPLES      21 PREDICATES      66 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-008-9155-y schema:about N0bd61c63a9994a7b81b33cf7fdce8328
2 N3fef8a8742db4a649ffe86d5a23006c3
3 N4131141f69cc4cc0a0bc99f1a1731f8e
4 N4918029c5c5b4a20bcd7cf9f16309030
5 N59ccedc512d84928838b80a46a893f32
6 N5c6b9de0c11d49eaa4a2f8217ded8cf3
7 N72c63ed1e8bb491fb5345cdb78a628dd
8 N7d6cb47e0d134b56bed1eb1185b2b211
9 N7f60a9fee9c44d48927826b490f76e8f
10 N971875dac0a34f3285efae0b1212847d
11 N9fbeb34827c444ea9f430dabd14e0b66
12 Nbfcd63e8393d48c3852382557a9dbeb6
13 Nc5c3521f708a48a983486a22d4d40cb9
14 Nd0ad1c5fd3724ddf9ce777b570270156
15 Nd18cb69b09f643b1a36717ef04b6f5ac
16 Nef02e14840d642f1b0325bc32e3f0488
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N9f05df94fa7943ee90ec0eada8401430
20 schema:citation sg:pub.10.1023/a:1006111117877
21 sg:pub.10.1023/a:1006262324959
22 sg:pub.10.1038/sj.bjc.6602926
23 sg:pub.10.1097/01.mp.0000052102.90815.82
24 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6
25 https://doi.org/10.1016/j.ccr.2007.08.030
26 https://doi.org/10.1016/j.copbio.2007.11.004
27 https://doi.org/10.1016/j.ejca.2006.11.019
28 https://doi.org/10.1056/nejm200103153441101
29 https://doi.org/10.1093/annonc/mdj905
30 https://doi.org/10.1093/annonc/mdl475
31 https://doi.org/10.1093/jnci/djk134
32 https://doi.org/10.1126/science.3798106
33 https://doi.org/10.1158/1078-0432.ccr-06-1304
34 https://doi.org/10.1200/jco.20.3.719
35 https://doi.org/10.1200/jco.2002.20.3.719
36 https://doi.org/10.1200/jco.2005.04.173
37 https://doi.org/10.1200/jco.2006.09.2775
38 https://doi.org/10.1200/jco.2007.14.8957
39 https://doi.org/10.3816/cbc.2001.n.017
40 https://doi.org/10.3816/cbc.2005.n.026
41 schema:datePublished 2009-04
42 schema:datePublishedReg 2009-04-01
43 schema:description To explore the clinical significance of the level of HER2/neu gene amplification in a homogenous cohort of 33 patients with HER2-positive metastatic breast cancer (MBC) and available tumor samples treated with a trastuzumab-based regimen, we retrospectively performed dual-color fluorescence in-situ hybridization test and correlated them for each patient with time-to-progression (TTP) and overall survival (OS). We obtained values of HER2/chromosome 17 centromere (CEP17) ratio ranging from 2.5 to 21 (median 7.2). At the Cox model there is indication that patients whose tumors have high-level HER2/CEP17 ratio have shorter TTP and OS than those with lower ratio, when treated with a trastuzumab-based regimen. Correlations do not reach the limits of statistical significance but no formal sample size calculation was performed due to the explorative nature of the study. If confirmed in larger cohorts of patients, HER2/CEP17 ratio could represent a reliable and economical predictor of response to trastuzumab-based therapy in MBC.
44 schema:genre research_article
45 schema:inLanguage en
46 schema:isAccessibleForFree true
47 schema:isPartOf N518ddd0ab95342499576544db987063a
48 N6b78af6a17204bf589585dbf0c910fbc
49 sg:journal.1094201
50 schema:name Level of HER2/neu gene amplification as a predictive factor of response to trastuzumab-based therapy in patients with HER2-positive metastatic breast cancer
51 schema:pagination 179
52 schema:productId N2adfea660b4e4d22aef7b1126b653615
53 N9505e06aaeed4be986b01b0d7206b973
54 Nae95be1cb57f41ce9c1da71302273455
55 Nb36b982c26794182ab25c55daa823d51
56 Nc5f06de94f454bca8a46d7146c6dbb36
57 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016696899
58 https://doi.org/10.1007/s10637-008-9155-y
59 schema:sdDatePublished 2019-04-15T09:13
60 schema:sdLicense https://scigraph.springernature.com/explorer/license/
61 schema:sdPublisher N68e693362a3543e08e70b41d2a00584f
62 schema:url https://link.springer.com/10.1007%2Fs10637-008-9155-y
63 sgo:license sg:explorer/license/
64 sgo:sdDataset articles
65 rdf:type schema:ScholarlyArticle
66 N0bd61c63a9994a7b81b33cf7fdce8328 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Retrospective Studies
68 rdf:type schema:DefinedTerm
69 N2adfea660b4e4d22aef7b1126b653615 schema:name dimensions_id
70 schema:value pub.1016696899
71 rdf:type schema:PropertyValue
72 N3fef8a8742db4a649ffe86d5a23006c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Predictive Value of Tests
74 rdf:type schema:DefinedTerm
75 N4131141f69cc4cc0a0bc99f1a1731f8e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
76 schema:name In Situ Hybridization, Fluorescence
77 rdf:type schema:DefinedTerm
78 N4918029c5c5b4a20bcd7cf9f16309030 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Trastuzumab
80 rdf:type schema:DefinedTerm
81 N518ddd0ab95342499576544db987063a schema:volumeNumber 27
82 rdf:type schema:PublicationVolume
83 N59ccedc512d84928838b80a46a893f32 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
84 schema:name Breast Neoplasms
85 rdf:type schema:DefinedTerm
86 N5c6b9de0c11d49eaa4a2f8217ded8cf3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
87 schema:name Antibodies, Monoclonal, Humanized
88 rdf:type schema:DefinedTerm
89 N68e693362a3543e08e70b41d2a00584f schema:name Springer Nature - SN SciGraph project
90 rdf:type schema:Organization
91 N6b78af6a17204bf589585dbf0c910fbc schema:issueNumber 2
92 rdf:type schema:PublicationIssue
93 N72c63ed1e8bb491fb5345cdb78a628dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
94 schema:name Adult
95 rdf:type schema:DefinedTerm
96 N7c7ccb1b011742489647d7b877df20fc rdf:first sg:person.01357677760.43
97 rdf:rest Ne2e0e4ca00694c6cbd7cf1cf8871299f
98 N7d6cb47e0d134b56bed1eb1185b2b211 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Gene Amplification
100 rdf:type schema:DefinedTerm
101 N7f60a9fee9c44d48927826b490f76e8f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
102 schema:name Female
103 rdf:type schema:DefinedTerm
104 N8d08e019a98f4414aad126b8e1c1ab20 schema:name Medical Oncology Unit, Cliniche Gavazzeni, Bergamo, Italy
105 rdf:type schema:Organization
106 N9505e06aaeed4be986b01b0d7206b973 schema:name nlm_unique_id
107 schema:value 8309330
108 rdf:type schema:PropertyValue
109 N971875dac0a34f3285efae0b1212847d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Genes, erbB-2
111 rdf:type schema:DefinedTerm
112 N9f05df94fa7943ee90ec0eada8401430 rdf:first sg:person.01223342332.02
113 rdf:rest Ncf1a0943e678450d81a66492cc7bd264
114 N9fbeb34827c444ea9f430dabd14e0b66 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Antineoplastic Agents
116 rdf:type schema:DefinedTerm
117 Nace648d2444c4929833c6f7c90c41f22 rdf:first sg:person.01213013520.94
118 rdf:rest Nbe2db17cb28141929be1b11896e16ca1
119 Nae95be1cb57f41ce9c1da71302273455 schema:name pubmed_id
120 schema:value 18663410
121 rdf:type schema:PropertyValue
122 Nb36b982c26794182ab25c55daa823d51 schema:name readcube_id
123 schema:value 4f8dd6d38b5348ae802a862450e05f0418acb3e4f2fc9d4658c21e7bd7bcaad5
124 rdf:type schema:PropertyValue
125 Nbe2db17cb28141929be1b11896e16ca1 rdf:first sg:person.01203725612.04
126 rdf:rest N7c7ccb1b011742489647d7b877df20fc
127 Nbfcd63e8393d48c3852382557a9dbeb6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Antibodies, Monoclonal
129 rdf:type schema:DefinedTerm
130 Nc5c3521f708a48a983486a22d4d40cb9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Disease-Free Survival
132 rdf:type schema:DefinedTerm
133 Nc5f06de94f454bca8a46d7146c6dbb36 schema:name doi
134 schema:value 10.1007/s10637-008-9155-y
135 rdf:type schema:PropertyValue
136 Ncf1a0943e678450d81a66492cc7bd264 rdf:first sg:person.0726433703.81
137 rdf:rest Nace648d2444c4929833c6f7c90c41f22
138 Nd0ad1c5fd3724ddf9ce777b570270156 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Aged
140 rdf:type schema:DefinedTerm
141 Nd18cb69b09f643b1a36717ef04b6f5ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Humans
143 rdf:type schema:DefinedTerm
144 Ne2e0e4ca00694c6cbd7cf1cf8871299f rdf:first sg:person.01277354144.26
145 rdf:rest rdf:nil
146 Nef02e14840d642f1b0325bc32e3f0488 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Middle Aged
148 rdf:type schema:DefinedTerm
149 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
150 schema:name Medical and Health Sciences
151 rdf:type schema:DefinedTerm
152 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
153 schema:name Oncology and Carcinogenesis
154 rdf:type schema:DefinedTerm
155 sg:journal.1094201 schema:issn 0167-6997
156 1573-0646
157 schema:name Investigational New Drugs
158 rdf:type schema:Periodical
159 sg:person.01203725612.04 schema:affiliation https://www.grid.ac/institutes/grid.417728.f
160 schema:familyName Masci
161 schema:givenName Giovanna
162 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203725612.04
163 rdf:type schema:Person
164 sg:person.01213013520.94 schema:affiliation https://www.grid.ac/institutes/grid.4527.4
165 schema:familyName Torri
166 schema:givenName Valter
167 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01213013520.94
168 rdf:type schema:Person
169 sg:person.01223342332.02 schema:affiliation https://www.grid.ac/institutes/grid.417728.f
170 schema:familyName Gullo
171 schema:givenName Giuseppe
172 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01223342332.02
173 rdf:type schema:Person
174 sg:person.01277354144.26 schema:affiliation https://www.grid.ac/institutes/grid.417728.f
175 schema:familyName Santoro
176 schema:givenName Armando
177 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01277354144.26
178 rdf:type schema:Person
179 sg:person.01357677760.43 schema:affiliation N8d08e019a98f4414aad126b8e1c1ab20
180 schema:familyName Salvini
181 schema:givenName Piermario
182 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01357677760.43
183 rdf:type schema:Person
184 sg:person.0726433703.81 schema:affiliation https://www.grid.ac/institutes/grid.417728.f
185 schema:familyName Bettio
186 schema:givenName Daniela
187 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726433703.81
188 rdf:type schema:Person
189 sg:pub.10.1023/a:1006111117877 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037590396
190 https://doi.org/10.1023/a:1006111117877
191 rdf:type schema:CreativeWork
192 sg:pub.10.1023/a:1006262324959 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047763314
193 https://doi.org/10.1023/a:1006262324959
194 rdf:type schema:CreativeWork
195 sg:pub.10.1038/sj.bjc.6602926 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012929330
196 https://doi.org/10.1038/sj.bjc.6602926
197 rdf:type schema:CreativeWork
198 sg:pub.10.1097/01.mp.0000052102.90815.82 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043809974
199 https://doi.org/10.1097/01.mp.0000052102.90815.82
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049278910
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1016/j.ccr.2007.08.030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034133737
204 rdf:type schema:CreativeWork
205 https://doi.org/10.1016/j.copbio.2007.11.004 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007493316
206 rdf:type schema:CreativeWork
207 https://doi.org/10.1016/j.ejca.2006.11.019 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022644824
208 rdf:type schema:CreativeWork
209 https://doi.org/10.1056/nejm200103153441101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031768583
210 rdf:type schema:CreativeWork
211 https://doi.org/10.1093/annonc/mdj905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031702252
212 rdf:type schema:CreativeWork
213 https://doi.org/10.1093/annonc/mdl475 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046368550
214 rdf:type schema:CreativeWork
215 https://doi.org/10.1093/jnci/djk134 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047572985
216 rdf:type schema:CreativeWork
217 https://doi.org/10.1126/science.3798106 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062621480
218 rdf:type schema:CreativeWork
219 https://doi.org/10.1158/1078-0432.ccr-06-1304 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049548242
220 rdf:type schema:CreativeWork
221 https://doi.org/10.1200/jco.20.3.719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064202789
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1200/jco.2002.20.3.719 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083941918
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.2005.04.173 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003035955
226 rdf:type schema:CreativeWork
227 https://doi.org/10.1200/jco.2006.09.2775 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026719751
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1200/jco.2007.14.8957 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019255637
230 rdf:type schema:CreativeWork
231 https://doi.org/10.3816/cbc.2001.n.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003466394
232 rdf:type schema:CreativeWork
233 https://doi.org/10.3816/cbc.2005.n.026 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001198940
234 rdf:type schema:CreativeWork
235 https://www.grid.ac/institutes/grid.417728.f schema:alternateName Humanitas Research Hospital
236 schema:name Laboratory of Cytogenetics, Istituto Clinico Humanitas IRCCS, Rozzano, (Milan), Italy
237 Oncology and Hematology Unit, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, Rozzano, (Milan), Italy
238 rdf:type schema:Organization
239 https://www.grid.ac/institutes/grid.4527.4 schema:alternateName Mario Negri Institute for Pharmacological Research
240 schema:name Clinical Oncology Research Unit, Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy
241 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...